Life Term Strategies

1. Huge Gains in Long Term
- Receive significant capital gains
- by investing in corporations
- (with wide economic moat & average peers’ net margin)
- In very very long term

2. Strong Periodic Cash Flow
- Maintain self-sufficient monthly cash flow
- Through dividend, gains on derivative & short term trading
- For re-investment to item # 1 mentioned above

3. Mind for Risk Management
- Ensure strong cash position
- Maintain low risk by continue monitor, analyze & feel:
economic trend & environment,
market condition & investors emotion
corporate performance & outlook
asset allocation & direction

4. Be a holy Christian investor:
- Invest in wisdom & varies ways, but consistent & not over nor under of what the Holy Bible expects a Jesus follower should be
- Keep regular & long term spiritual growth
Continue experience God @ finance market
Aim for life transform opportunities
- Even though it may not teach Billy & Bilibala what stocks to invest nor how to make more, more & more $

9.10.2009

Procter & Gamble reaffirms Q1 EPS

Procter & Gamble reaffirms Q1 EPS, FY10 EPS and revs guidance; sees return to organic sales growth in second quarter Co reaffirms guidance for Q1 (Sep), sees EPS of $0.95-1.00 vs. $0.97 First Call consensus; co also sees organic sales down 7-10% YoY vs -9.9% consensus. Co reaffirms guidance for FY10 (Jun), sees EPS of $3.65-3.80, excluding the sale of its Pharma biz, vs. $3.68 consensus; co also reaffirms its organic sales outlook of up 1-3% vs the -0.6% consensus. The co also stated it expects to return to organic sales growth in the October - December quarter compared to prior year levels, following two quarters of organic sales declines.

"We clearly see that we are approaching an inflection point in P&G's organic sales trends. The innovations we are launching and the investments we are making are having an impact in the market. In addition, comparisons to prior year results will get easier as we move into the second quarter."

Co also provided guidanec including the sales of the Pharmaceutical biz; it now sees FY10 EPS of $3.99-4.12. This includes a one-time net increase in earnings of $0.44 per share from the sale of the Pharmaceutical business, which will be partially offset by $0.10 to $0.12 per share of earnings dilution related to the transaction.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.

Bilibala comments:
Great!! Looks like the consumer staple sector has started the recovery journey. Let's see whether the actual will follow through according to Management's expectations.
at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
The information provided in the entire blog is not intended to provide legal, accounting, tax or specific investment advice. The information presented was obtained from sources believed to be reliable; however, I cannot represent that it is accurate or complete. I assume no responsibility for any losses, whether direct, special or consequential, that arise out of the use of this information. This information is subject to change without notice. Stock performance are not guaranteed, their prices change frequently and past performance may not be repeated. Please do your own investigation, or contact your own professional advise, before investing.